Bluelinx Holdings Inc. – Consensus Indicates Potential 55.0% Upside

DirectorsTalk Interviews

Bluelinx Holdings Inc. with ticker code (BXC) now have 5 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 127 and 100 calculating the average target price we see 108.4. Now with the previous closing price of 69.92 this is indicating there is a potential upside of 55.0%. The day 50 moving average is 74.52 and the 200 moving average now moves to 77.96. The market capitalisation for the company is $660m. Company Website: https://www.bluelinxco.com

The potential market cap would be $1,024m based on the market concensus.

BlueLinx Holdings Inc., together with its subsidiaries, distributes residential and commercial building products in the United States. The company distributes specialty products comprising engineered wood, industrial products, cedar, moulding, siding, metal, and insulation products; and structural products include lumber, plywood, oriented strand boards, rebars and remesh, spruce, and other wood products primarily that are used for structural support in construction projects. It also provides various value-added services and solutions to customers and suppliers. The company serves dealers, specialty distributors, national home centers, and manufactured housing customers through a network of distribution centers. BlueLinx Holdings Inc. was incorporated in 2004 and is headquartered in Marietta, Georgia.

Share on:

Latest Company News

Criterium Energy nears first gas as Indonesian project reaches 70% completion

Criterium Energy is nearing first gas in Indonesia while stronger cash generation supports further field development.

India’s smart meter rollout is building a broader digital grid opportunity

India’s smart-meter rollout is developing into a wider digital-grid ecosystem spanning connected hardware, communications, utility software, cybersecurity and energy analytics.

Genflow Biosciences links ageing science with MASH research

MASH gives Genflow Biosciences a defined opportunity to explore how its SIRT6-based gene therapy research could address metabolic liver damage, inflammation and fibrosis.

GCP Infrastructure reports 8.0% portfolio yield and stronger balance sheet

GCP Infrastructure Investments has reported a 98.60 pence net asset value, portfolio valuation of £810.4 million and further debt and asset sale updates.

Plus500 expands US trading offering with new Single Stock Futures

Plus500 has launched Single Stock Futures in the US, broadening customer access to CME Group-listed contracts and leading US stocks.

Clarkson reports record first-half profit and raises interim dividend

Clarkson Plc reported record first-half profit, lifted interim dividend and said full-year performance is expected to be materially ahead of market expectations.

    Search